Prior to his appointment as Chief Executive Officer and President of the Company, Mr. Kim was the General Counsel and a Senior Vice President of Dong-A ST and Dong-A Socio Group, a Korean-based group of companies mainly engaged in the research, development, production and sale of pharmaceuticals, medical devices and APIs and Mr. Kim has been serving as a member of the Company’s Board since July 2021. Mr. Kim previously served as Executive Director of Dong-A ST from 2018 through 2020 and as Head of International Legal Affairs for Dong-A Socio Holdings Co., Ltd., a Korean-based holdings company for the Dong-A Socio group of companies from 2012 to 2018. During his time at Dong-A ST and Dong-A Socio Holdings, he negotiated many significant transactions, including licensing and investment transactions. Since April 2021, Mr. Kim has served as a director of AnaPath Services GmbH, a private, Swiss-based provider of scientific research and development services. Mr. Kim previously served as legal counsel to SK Energy Co., Ltd. and SK Innovation Co., Ltd. He received his Bachelor of Law degree from Soongshil University in Korea, and obtained his Juris Doctor from Washington University School of Law.
Dr Harrison earned his medical degree from the University of Mississippi School of Medicine. He completed his internal medicine residency and gastroenterology fellowship at Brooke Army Medical Center and a 4th year advanced liver disease fellowship at Saint Louis University. He completed more than 20 years of active duty in the U.S. Army rising to the rank of Colonel, before retiring in 2016.
Dr Harrison is currently a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford. He is internationally known for studies in NAFLD/NASH (particularly drug development) with over 300 peer reviewed publications and an H Index of 101. Dr Harrison currently serves as the founder and chairman for both Pinnacle Clinical Research and Summit Clinical Research (an internationally recognized integrated research organization with over 100 sites worldwide) in San Antonio, Texas. He is the lead PI for numerous NASH development programs.
Dr. Mi-Kyung Kim has served as a Vice President, leading the overall new drug discovery research for metabolic and immune-mediated diseases at Dong-A ST. She has more than 25 years of experience in the pharmaceutical industry. She has a high level of understanding of new drug development, experiencing both domestic and global clinical development, as well as overall new drug development from initial drug discovery to new drug approval while leading the project. She has specialized research experience focusing on chronic endocrine/cardiometabolic disease era such as diabetes, obesity, NASH, chronic kidney disease and osteoporosis. During her career at Dong-A, she has led numerous projects, including a novel dipeptidyl peptidase inhibitor (evogliptin, Suganon®), which became the world ninth approved product for the treatment of type 2 diabetes. DA-1241 and DA-1726 are new drug candidates for metabolic diseases, and she has been establishing drug evaluation and development strategies while establishing the concept of drugs from the initial target selection stage of these two projects to the present. Academically, after she graduated from the College of Pharmacy at Ewha Womans University in Korea, she studied cancer metastasis and beta cell biology/proteomics in the same graduate school.
Robert Homolka is an experienced clinical development operations executive with a strong track record of improving efficiency and compliance in clinical development programs. He has successfully led cross-functional teams in designing and executing clinical trials, managing budgets, and timelines. Notable for his cost-saving initiatives and effective vendor negotiations, he has integrated FDA and ICH regulatory standards into company practices. With extensive experience managing Phase I to IV clinical research projects, He has launched and optimized clinical operations for multiple biopharmaceutical companies. He has managed clinical trial activities across various therapeutic areas and played key roles in trials for compounds such as ZD4522, AZD-7371, NXY-059, and others. He has held senior roles at Cyclone Consulting, Adiso Therapeutics, Shire/Takeda Pharmaceuticals, and AstraZeneca Pharmaceuticals, overseeing clinical operations and ensuring regulatory compliance. He has a Master of Science in Integrated Pharmacology, a Master of Business Administration, and a Bachelor of Science in Microbiology. He has presented at industry conferences and contributed to publications in the field.
Sung-Jin Kim has excelled in various roles at Dong-A ST. As a Corporate Planning Team Lead, he directly supports the CEO, overseeing crucial tasks like shareholders’ meeting, strategic planning, budget management, and organizational development. He also served as a Clinical Study Manager, managing Phase I, II, and III trials for evogliptin, a DPP-IV inhibitor for the treatment of type 2 diabetes. Furthermore, as a BD & License Assistant Manager, he reviewed international drug licenses and facilitated collaborations with global partners. He holds an MBA from Korea University and a Bachelor of Science in Pharmacy from Seoul National University. His multifaceted background and contributions highlight his capability to excel in corporate strategy at NeuroBo.